Canadian Cancer Society logo
You are here: 
A-|A|A+

Dr Sheldon Fine

Sheldon's medical education and medical oncology training was obtained at the University of Toronto and the Princess Margaret Hospital. Following completion of his fellowship program, he did postgraduate work with the late Dr. Ron Buick, evaluating drug sensitivity in stem cell cultures. He worked as a staff physician at the Princess Margaret Hospital between 1981 and 1987, and had an opportunity to participate in and co-author one of the seminal projects evaluating new treatments for colorectal cancer.

In 1987, he moved to the Credit Valley Hospital and helped to establish the Oncology Program at this organization. Working with a strong clinical and administrative team, he helped to plan, develop and subsequently build the Carlo Fidani Peel Regional Cancer Centre. The centre opened in 2005 and now records almost 100,000 patient encounters per year.

Professionally, Sheldon has had the opportunity to work with the team at CCO to initiate and formulate the development of what is now the Colon Cancer Check Program. He has had the opportunity to serve as Section Chair for Medical Oncology at the Ontario Medical Association and worked with the medical oncologists in Ontario to develop the first alternate payment plan. Currently, he serves in the role of Chief of Oncology at the Credit Valley Hospital.

His interest in quality, patient-centered care comes from experiences as a caregiver both for his parents and a sister who succumbed to cancer. These journeys have helped him maintain a grounded sense of humility in his own practice, recognition of the important role of patient, family and professional partnerships, and the need to constantly explore novel approaches to the delivery of health services.

A-|A|A+

Stories

Dr Robert Bristow Dr Robert Bristow’s research in prostate cancer could help guide personalized treatment.

Learn more

Clinical trial discovery improves quality of life

Illustration of test tubes

A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.

Learn more